CRSP

CRISPR Therapeutics AG: 2024 Annual Report (10-K) Summary

Business Context and Reporting Period

This summary covers the fiscal year ended December 31, 2024. CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR-based therapeutics. The company's lead product, CASGEVY (exagamglogene autotemcel), is the world's first approved CRISPR-based therapy, indicated for severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). CASGEVY is co-developed and co-commercialized with Vertex Pharmaceuticals. The company maintains a diversified pipeline across four core franchises: hemoglobinopathies, CAR T cell therapies, in vivo gene editing, and Type 1 diabetes.

Key Financial Metrics (Year Ended Dec 31, 2024)

Note: The company does not report gross margins or net profit margins as it is a pre-commercial biotechnology firm with significant operating losses.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by approximately 90% to $37.3 million from $371.2 million in 2023. This was primarily due to the recognition of a $200 million milestone payment in 2023 related to the FDA approval of CASGEVY, which did not recur in 2024. 2024 collaboration revenue consisted of $35 million in research milestones from Vertex.
• Increased Net Loss: Net loss widened to $366.3 million from $153.6 million in 2023. This increase was driven by the significant drop in revenue, partially offset by a reduction in operating expenses.
• Expense Reduction: Total operating expenses decreased by $89.9 million to $503.9 million. Research and development (R&D) expenses fell by $66.7 million, largely due to decreased external R&D costs and sublicense fees. Collaboration expense, net, decreased by $20.0 million.
• Capital Raising: In February 2024, the company completed a registered direct offering, raising approximately $279 million in net proceeds. Additionally, the company utilized its At-The-Market (ATM) facility to raise an additional $21.7 million.
• Interest Income: Other income, net, increased to $103.9 million from $71.8 million, driven by higher interest income on the company's substantial cash and marketable securities portfolio.

Guidance, Outlook, and Risks

Outlook and Liquidity: Management expects its cash, cash equivalents, and marketable securities of $1.9 billion as of December 31, 2024, to be sufficient to fund operations for at least the next 24 months. The company anticipates continuing to incur significant operating losses for the foreseeable future as it advances its pipeline and supports the commercialization of CASGEVY.

Cost Deferral Expiration: A critical financial change occurs in 2025. Under the joint development agreement with Vertex, CRISPR had the option to defer its share of CASGEVY program costs exceeding $110.3 million annually for 2022, 2023, and 2024. This deferral option expires in 2025, meaning the company expects its share of CASGEVY expenses to increase significantly and exceed its share of revenue for the foreseeable future.

Key Risks and Contingencies:

• Regulatory and Clinical Uncertainty: Success depends on advancing product candidates (e.g., CTX112, CTX131, CTX310, CTX320) through clinical trials and obtaining regulatory approvals. Early positive results are not predictive of later outcomes.
• Intellectual Property (IP): The company faces ongoing IP litigation and uncertainty regarding the CRISPR/Cas9 patent landscape, including interferences with the Broad Institute and other third parties. The core IP is jointly owned, which may limit enforcement rights.
• Manufacturing Complexity: Gene editing products are novel and complex to manufacture. The company relies on both its internal facility in Framingham, MA, and third-party contract manufacturers.
• Partnership Dependence: Vertex controls the development and commercialization of CASGEVY. Disagreements or delays with Vertex could materially harm the business.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $1.9 billion cash position against the projected increase in CASGEVY cost-sharing obligations starting in 2025.
• CASGEVY Commercialization: Monitor Vertex's commercial performance of CASGEVY, as CRISPR's revenue share (40%) and cost obligations are directly tied to this program's profitability.
• Pipeline Milestones: Track clinical data readouts for key wholly-owned programs: CTX112 (CAR T), CTX131 (CAR T), CTX310 (in vivo ANGPTL3), and CTX320 (in vivo Lp(a)).
• IP Litigation Status: Review updates on the '115 interference and other patent challenges involving the Broad Institute and other competitors, as these impact the freedom to operate.
• Cost Deferral Impact: Assess the specific financial impact of the expiration of the CASGEVY cost deferral mechanism in 2025 on future operating losses.